DOTBIOHK LIMITED
The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
DotBioHK Limited (“DotBioHK”) is a Hong Kong-based, wholly-owned subsidiary of DotBio Pte Ltd (DotBio), a Singapore-based biopharmaceutical start-up focusing on next-generation multi-specific antibody drugs. DotBio has a proprietary humanized, stable Domain Therapeutic Antibody (“Dotbody”) technology that will revolutionize multi-specific therapies, antibody-drug conjugates and CAR-T therapies. DotBio currently possesses proprietary state-of-art DotBody and Fab phage display libraries, as well as numerous pre-clinical assets in the immune-oncology field. Meanwhile, DotBioHK will have a major focus on non-oncology therapeutic areas.